Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 483.5 DKK 2.49% Market Closed
Market Cap: 97.7B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Common Stock
kr66m
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
1%
Zealand Pharma A/S
CSE:ZEAL
Common Stock
kr71m
CAGR 3-Years
18%
CAGR 5-Years
15%
CAGR 10-Years
12%
Ascendis Pharma A/S
NASDAQ:ASND
Common Stock
€7.8m
CAGR 3-Years
-84%
CAGR 5-Years
4%
CAGR 10-Years
35%
B
Bavarian Nordic A/S
CSE:BAVA
Common Stock
kr781.2m
CAGR 3-Years
7%
CAGR 5-Years
19%
CAGR 10-Years
12%
F
Fluoguide AS
STO:FLUO
Common Stock
kr1.2m
CAGR 3-Years
5%
CAGR 5-Years
89%
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Common Stock
kr429.7m
CAGR 3-Years
17%
CAGR 5-Years
20%
CAGR 10-Years
14%
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology

Genmab A/S is a cutting-edge biotechnology company based in Denmark, renowned for its pioneering approach to developing differentiated antibody therapies for the treatment of cancer. Founded in 1999, the company focuses on harnessing the power of the immune system to combat various malignancies. Its flagship product, Darzalex (daratumumab), has transformed treatment protocols for multiple myeloma, achieving robust sales and establishing Genmab as a formidable player in the oncology landscape. The company's innovative platform combines proprietary technologies and skilled teams to create next-generation therapies, underscoring its commitment to improving patients' lives through targeted and effective cancer treatment solutions. As Genmab continues to build on its success, it is also expanding its pipeline with a diverse array of promising assets in various stages of clinical development. Not only does this validate its research capabilities, but it also positions Genmab for substantial future growth. The company's strategic collaborations with major pharmaceutical partners, such as Johnson & Johnson, further amplify its reach and resource capabilities, fostering a collaborative approach to accelerate drug development. With a solid financial standing and a focus on sustained innovation, Genmab A/S presents an intriguing investment opportunity for those looking to tap into the evolving landscape of biotechnology and oncology therapeutics.

GMAB Intrinsic Value
2 507.16 DKK
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Genmab A/S's Common Stock?
Common Stock
66m DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Common Stock amounts to 66m DKK.

What is Genmab A/S's Common Stock growth rate?
Common Stock CAGR 10Y
1%

Over the last year, the Common Stock growth was 0%.

Back to Top